Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more
Incyte Corporation (INCY) - Total Assets
Latest total assets as of December 2025: $6.96 Billion USD
Based on the latest financial reports, Incyte Corporation (INCY) holds total assets worth $6.96 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Incyte Corporation - Total Assets Trend (1993–2025)
This chart illustrates how Incyte Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Incyte Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
Incyte Corporation's total assets of $6.96 Billion consist of 72.2% current assets and 27.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.5% |
| Accounts Receivable | $1.02 Billion | 14.7% |
| Inventory | $101.06 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $117.13 Million | 1.7% |
| Goodwill | $133.00 Million | 1.9% |
Asset Composition Trend (1993–2025)
This chart illustrates how Incyte Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Incyte Corporation's current assets represent 72.2% of total assets in 2025, a decrease from 89.2% in 1993.
- Cash Position: Cash and equivalents constituted 44.5% of total assets in 2025, down from 88.1% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 14.7% of total assets.
Incyte Corporation Competitors by Total Assets
Key competitors of Incyte Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Incyte Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Incyte Corporation generates 0.74x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Incyte Corporation generates $ 18.49 in net profit.
Incyte Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.32 | 1.97 | 3.93 |
| Quick Ratio | 3.25 | 1.94 | 3.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.51 Billion | $ 1.60 Billion | $ 1.83 Billion |
Incyte Corporation - Advanced Valuation Insights
This section examines the relationship between Incyte Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.88 |
| Latest Market Cap to Assets Ratio | 2.21 |
| Asset Growth Rate (YoY) | 27.8% |
| Total Assets | $6.96 Billion |
| Market Capitalization | $15.36 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Incyte Corporation's assets at a significant premium ( 2.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Incyte Corporation's assets grew by 27.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Incyte Corporation (1993–2025)
The table below shows the annual total assets of Incyte Corporation from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.96 Billion | +27.80% |
| 2024-12-31 | $5.44 Billion | -19.73% |
| 2023-12-31 | $6.78 Billion | +16.11% |
| 2022-12-31 | $5.84 Billion | +18.40% |
| 2021-12-31 | $4.93 Billion | +38.54% |
| 2020-12-31 | $3.56 Billion | +3.92% |
| 2019-12-31 | $3.43 Billion | +29.52% |
| 2018-12-31 | $2.65 Billion | +14.90% |
| 2017-12-31 | $2.30 Billion | +40.52% |
| 2016-12-31 | $1.64 Billion | +62.65% |
| 2015-12-31 | $1.01 Billion | +21.37% |
| 2014-12-31 | $830.07 Million | +31.85% |
| 2013-12-31 | $629.57 Million | +90.54% |
| 2012-12-31 | $330.42 Million | +0.44% |
| 2011-12-31 | $328.96 Million | -32.81% |
| 2010-12-31 | $489.58 Million | -31.28% |
| 2009-12-31 | $712.39 Million | +206.55% |
| 2008-12-31 | $232.39 Million | -15.71% |
| 2007-12-31 | $275.69 Million | -22.03% |
| 2006-12-31 | $353.60 Million | -5.48% |
| 2005-12-31 | $374.11 Million | -27.63% |
| 2004-12-31 | $516.92 Million | +36.19% |
| 2003-12-31 | $379.55 Million | -31.26% |
| 2002-12-31 | $552.14 Million | -21.74% |
| 2001-12-31 | $705.56 Million | -20.44% |
| 2000-12-31 | $886.82 Million | +299.65% |
| 1999-12-31 | $221.90 Million | -3.65% |
| 1998-12-31 | $230.30 Million | +19.26% |
| 1997-12-31 | $193.10 Million | +188.64% |
| 1996-12-31 | $66.90 Million | +15.74% |
| 1995-12-31 | $57.80 Million | +101.39% |
| 1994-12-31 | $28.70 Million | +63.07% |
| 1993-12-31 | $17.60 Million | -- |